Votexetine gæti orðið fyrsta hugræna meðferðarlyfið við þunglyndi í Evrópu

The new indications of the antidepressant drug Brintellix of Lingbei pharmaceutical have been supported by CHMP. This drug will soon become the first antidepressant approved in the EU to improve the cognitive function of patients with depression. The new indications are based on the results of the connecting test. The results show that when compared with placebo, vortioxetine and Lilly's antidepressant competitive product duloxetine can better improve various cognitive indexes of patients.

People with severe depression usually report a series of cognitive symptoms, including obvious difficulties in thinking, attention, and memory of new information, which can damage patients' self-confidence and lead to social disharmony. Although cognitive problems have been well recognized in other mental diseases such as schizophrenia, there are few studies on their impact on depression.

Við erum ánægð með að vortioxetin hafi fengið jákvæðar athugasemdir frá CHMP, sérstaklega stöðu vitsmunalegrar skerðingar sem hefur áhrif á meðferðarútkomu flestra sjúklinga, sagði Pedersen, forstöðumaður Lingbei rannsókna og þróunar. Uppörvandi gögnin sem við höfum séð við að takast á við vitsmunalegan sjúkdóma leiða okkur til að trúa því að vortioxetín geti hjálpað mörgum sjúklingum að meðhöndla þunglyndi sitt.

Votexetine has been listed in the United States for only more than a year, and it is gradually lifted in the whole EU. Last September, it was listed in Denmark, Lingbei's hometown. It is reported that this drug is the fastest-growing new antidepressant in the United States in the past three years. This drug is jointly listed by Lingbei and Takeda in the United States.

Þetta eru góðar fréttir fyrir Lingbei vegna þess að það þarf ný lyf til að bæta upp áhrifin eftir að einkaleyfi á gamla þunglyndislyfinu Idprem rennur út. Yidepulum var stórsigur lyf með árlega sölu upp á nokkra milljarða dollara, sem hefur orðið fyrir áhrifum af samkeppni samheitalyfja.

Votexetine sold 188 million kroner (27 million) in six EU markets last year, compared with 83 million kroner in the fourth quarter alone, so it still has some ways to catch up with Idem. Although Idprem no longer has a market franchise, it still sold 4.6 billion kroner. The Danish company also has long-acting schizophrenic drug aripiprazole and an alcohol addiction treatment drug nalmefene, which can help vortioxetine increase the company's revenue again.